Naxitamab

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1].

Product Specifications

CAS Number

[1879925-92-4]

Product Name Alternative

Naxitamab-gqgk; Humanized 3F8; Hu3F8

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/naxitamab.html

Purity

99.84

Solubility

10 mM in DMSO

Smiles

[Naxitamab]

Molecular Weight

(144.38 kDa)

References & Citations

[1]Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1 (4) :477-486.|[2]Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81 (2) :291-296.